Mednet Logo
CommunityRadiation Oncology

Would you consider omitting PMRT in cT3N0 triple negative breast cancer with a pCR?

In a young patient <30 years old with large pre-chemotherapy, multifocal disease with pCR following mastectomy, would you consider extrapolating the results of NSABP-51 and omitting PMRT? Why or why not?
3 Answers
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Allegheny Health Network, Pittsburgh
Answered on

These are challenging cases with limited data as Dr. @Dr. First Last notes. In a young patient with cT3N0 disease with a pCR, I would discuss the lack of data and that RT may reduce rates of LRR with unclear survival benefits. I would discuss the pros and cons but I would be comfortable offering the...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Beth Israel Deaconess Medical Center
Answered on

There is a paucity of information on the risk of local-regional recurrence following mastectomy in patients following neoadjuvant chemotherapy (NACT). This is particularly so for those who present with clinical T3N0 cancers. The largest such cohort is from the NSABP B-18 and B-27 trials, performed f...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · Varian Medical Systems/Allegheny health network
Answered on

My default was PMRT for T3N0 TNBC with pCR as data available was limited. Now with B51 showing no benefit with about 20% being T3N1 questions routine use of PMRT. Any benefit had to be weighed against the downside especially if reconstruction was also done.

Join for free or sign in to see the full answer